Signage outside Merck &; Co. headquarters in Kenilworth, New Jersey, U.S. Photographer: Christopher Occhicone/Bloomberg Viral sequencing done so far have showed it is effective against all coronavirus variants, including Delta, Merck said.
The interim efficacy data on the drug, which has been developed with Ridgeback Biotherapeutics, had heavily impacted the shares of COVID-19 vacine makers when it was released last week.
Existing drugs include Gilead Sciences Inc's infused antiviral remdesivir and generic steroid dexamethasone, both of which are generally only given once a patient has already been hospitalized.
Meanwhile, monoclonal antibody drugs from Regeneron Pharmaceuticals Inc and Eli Lilly have so far seen only limited uptake due to the difficulty in administering them.
(Reporting by Manas Mishra and Leroy Leo in Bengaluru; Editing by Arun Koyyur)
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email letters@dailymaverick.co.za